Related Experiment Video
Updated: Aug 11, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Mechanisms of antiepileptic drug resistance
1Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK. sisodiya@ion.ucl.ac.uk
Purpose Of Review:
The present review considers new developments in the study and our understanding of resistance to treatment with antiepileptic drugs in epilepsy.
Recent Findings:
Studies suggest that mechanisms of resistance to drug treatment that operate in other diseases may also be relevant in human and animal drug-resistant epilepsy. Immunohistochemical and molecular genetic data show that there is overexpression of a number of genes and proteins that mediate nonspecific resistance to drug treatment. In particular, there is upregulation of P-glycoprotein and multidrug resistance-associated proteins 1 and 2. These proteins appear to be expressed in cerebral parenchymal cell populations that do not normally do so. Work in animal models suggests that these proteins are able to reduce the local concentration of antiepileptic drugs. Although these proteins are therefore good candidates for mediators of drug resistance, there is still limited proof that they are functionally important in human drug-resistant epilepsy.
Summary:
Careful attention needs to be given to the identification and confirmation of the practical importance of mechanisms postulated to underlie drug resistance in human epilepsy. If certain mechanisms are shown to be involved, then new therapeutic options for drug-resistant human epilepsy may be forthcoming.
Insights
Mechanisms of drug resistance in epilepsy may involve proteins like P-glycoprotein, which reduce antiepileptic drug concentrations. Further research is needed to confirm their role in human drug-resistant epilepsy and develop new treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Epilepsy treatment often faces challenges due to drug resistance.
- Understanding resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To review recent advancements in understanding antiepileptic drug resistance in epilepsy.
- To explore potential mechanisms underlying treatment resistance.
Main Methods:
- Review of existing studies on drug resistance mechanisms.
- Analysis of immunohistochemical and molecular genetic data.
- Examination of findings from animal models of epilepsy.
Main Results:
- Mechanisms of drug resistance seen in other diseases may apply to epilepsy.
- Overexpression of genes/proteins, including P-glycoprotein and multidrug resistance-associated proteins, is observed.
- These proteins may reduce antiepileptic drug concentration in the brain, but their functional importance in human epilepsy requires more evidence.
Conclusions:
- Confirmation of the practical significance of identified resistance mechanisms in human epilepsy is essential.
- Identifying key mechanisms could lead to novel therapeutic strategies for drug-resistant epilepsy.
Related Concept Videos
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...